Veterinary Medicinal Products Regulations, 2024
Table of Provisions (40)
Statutory Text (40 Articles)
L.N. 335 of 2024
VETERINARY SERVICES ACT
(CAP. 437)
Veterinary Medicinal Products Regulations, 2024
IN EXERCISE of the powers conferred by articles 30, 32, 70 and
73 of the Veterinary Services Act, the Minister responsible for
veterinary services, after consultation with the Director Veterinary
Services, has made the following regulations:-
(1) The title of these regulations is the Veterinary
Medicinal Products Regulations, 2024.
(2) These regulations implement the requirements of
Regulation (EU) 2019/6 of the European Parliament and of the Council
of 11 December 2018 on veterinary medicinal products and repealing
Directive 2001/82/EC and regulate other matters of Regulation (EU)
2019/6.
(3) These regulations shall also be applicable to veterinarians
referred to in Regulation (EU) 2019/6.
(4) These regulations shall come into force within two (2)
months from their date of publication in the Gazette.
(5) Regulation 17(2) shall come into force within two (2) years
from the date of publication of these regulations.
(1)
In these regulations, unless the context otherwise
requires
"Act" means the Veterinary Services Act;
"Agency" means the European Medicines Agency
established by Regulation (EC) No 726/2004 of the European
Parliament and of the Council of 31 March 2004 laying down
Community procedures for the authorisation and supervision of
medicinal products for human and veterinary use and
establishing a European Medicines Agency;
"applicant" means the person who applies with the Director
to obtain any kind of authorisation as the case may be;
"broker" means a person who acts as an intermediary in
arranging sale of veterinary medicinal products between two (2)
or more parties who are authorised to distribute veterinary
medicinal products by means of a wholesale distribution
authorization, without the veterinary medicinal products being
transported or stored by him;
"brokering" means the activity of the broker in relation to
the sale or purchase of veterinary medicinal products, except for
wholesale distribution, which do not include physical handling of
the veterinary medicinal product by the broker, and which consist
of negotiating independently and on behalf of another person;
"country of source" means a Member State of the European
Union or a country in the European Economic Area;
"Director" means the Director Veterinary Services who
shall be a warranted veterinary surgeon or an officer nominated
by him;
"electronic veterinary prescription" means a veterinary
prescription making use of the technology framework made
available by the Director that allows veterinary surgeons to issue
veterinary prescriptions through electronic media and that is
available to those persons who are authorized to dispense
veterinary medicinal products;
"food" shall have the same meaning as assigned to it in the
Food Safety Act;
"imported" means the act of acquiring veterinary medicinal
product or part thereof, whether for the purposes of profit or non-
profit, from a third country;
"investigational veterinary medicinal product’" means a
pharmaceutical form of an active substance or placebo being
tested or used as a reference in a clinical trial, including products
already with a marketing authorisation but used or assembled
(formulated or packaged) in a way which is different from the
authorised form, or when used for an unauthorised indication, or
when used to gain further information about the authorised form;
"licensed veterinary establishment" shall have the same
meaning as that assigned to it in the Private Veterinary S.L. 437.106.
Establishments (Licensing) Regulations;
"medicinal products for human use" shall have the same
meaning as that assigned to it in the Medicines Act;
"Member State" means a State which is a member of the
European Union;
"narcotic drugs" means the substances present on the
Yellow List established by the International Narcotics Control
Board in accordance with the Protocol of 25 March 1972
amending the Single Convention on Narcotic Drugs, 1961;
"pharmacist" means a person who is enlisted in the Register
of Pharmacists kept by the Pharmacy Council in accordance with
article 17 of the Health Care Professions Act;
"premises" means the premises used for, or in connection
with, any premises authorised or licensed by the Director, as the
case may be;
"prescribing" means the act of preparing a veterinary
prescription by a veterinary surgeon whether on paper or through
electronic media;
"psychotropic drugs" means the substances listed in the
Third Schedule to the Medical and Kindred Professions
Ordinance and those substances listed on the Green List prepared
by the International Narcotics Control Board in accordance with
the Convention on Psychotropic Substances of 1971, as
amended;
"Regulation (EU) 2019/6" means Regulation (EU) 2019/6
of the European Parliament and of the Council of 11 December
2018 on veterinary medicinal products and repealing Directive
2001/82/EC;
"responsible person" means the technically competent
person referred to in Article 101 of Regulation (EU) 2019/6;
"Single Convention" means the Single Convention on
Narcotic Drugs adopted at New York on the 30th March 1961, as
subsequently amended by the Protocol adopted in Geneva on the
25th March, 1972;
"suitably learned person" means any person included in the
Register of the Professions and Trades Supplementary to the
Veterinary Profession provided for in the Act who may dispense
veterinary medicinal products of category OTC under the
supervision of a veterinary surgeon or pharmacist and dispense
others of category GS without this supervision;
"veterinary pharmacy" means any premises licensed in
accordance with article 62 of the Act in which any veterinary
medicinal product is kept, or from where it is sold, dispensed or
supplied directly to the public by retail, but shall not include
dispensing of treatments from veterinary establishments and
dispensing during out calls by veterinary surgeons;
"veterinary surgeon" means a person who has a warrant
granted in accordance with article 43 of the Act;
"wholesale distributor of veterinary medicinal products"
means the holder of a valid wholesale distribution authorisation
referred to in Article 99(1) of Regulation (EU) 2019/6.
(2) Unless the context otherwise requires, words and phrases
used in these regulations which are not herein defined shall have the
same meaning assigned to them in the Act
Provided that words and phrases used in these regulations
which are neither defined in these regulations nor in the Act shall have
the same meaning assigned to them in Regulation (EU) 2019/6.
The Director shall determine the language or languages of Languages.
the summary of the product characteristics and the information on the
labelling and on the package leaflet of veterinary medicinal products to
be marketed in the territory of Malta and make this information public.
The package leaflet of a veterinary medicinal product may Package leaflet.
be made available on paper, electronically, or both of them.
(1) For the purposes of Article 5(6) of Regulation (EU) Exemptions
from a
2019/6, the applicant shall submit an application in the form provided marketing
authorisation.
for by the Director and shall pay the established fee
Provided that the veterinary medicinal product shall only be
placed on the market when the authorisation is issued by the Director.
(2) The exemption stipulated under Article 5(6) of Regulation
(EU) 2019/6 shall only be granted at the discretion of the Director.
(3) The holder of an authorisation in accordance with this
regulation shall notify the Director within fifteen (15) days of
becoming aware of any adverse reaction and shall keep records of such
incidents
Provided that the records provided for in this regulation
shall be kept by a holder of an authorisation in accordance with this
regulation for five (5) years and shall be made available to the Director
upon his request.
(4) The Director may publish a list of active substances that
may be used in veterinary medicinal products authorised in accordance
with this regulation. This list shall specify the species of non-food
producing animals for which the active substances are approved. This
list may also specify the manner in which the product containing the
active substances are to be administered.
(5) The Director may reject an application or may suspend and,
or revoke the authorisation granted in accordance with this regulation
if any one (1) or more of the following occur
(a)
adverse reactions are reported and confirmed;
(b) it is demonstrated, at any time after authorisation, that
the risk-benefit is unfavourable;
(c) the product contains active substances that are re-
classified as narcotic or psychotropic drugs;
(d) any one (1) of the ingredients in the product is not
included anymore in the list of active substances mentioned in
sub-regulation (4); and
(e) it is reported and is verified by the Director that the
product is not being used on animals as established in Article
5(6) of Regulation (EU) 2019/6.
(6) The products authorised under this regulation shall be
labelled with the following
(a)
the name of the veterinary medicinal product;
(b)
the pharmaceutical form;
(c)
the name and strength of each active substance;
(d)
the route of administration;
(e)
the batch number;
(f)
the expiry date;
(g) a statement to the effect of "For administration on
non-food producing animals only. Veterinary medicinal product
authorised in accordance with Article 5(6) of Regulation (EU)
2019/6";
(h)
the target species;
(i)
storage instructions, if applicable;
(j)
therapeutic indications, if applicable;
(k)
contra-indications, if applicable; and
(l) interaction with other medicines and other forms of
interaction, if applicable.
(7) The authorisation granted in accordance with this regulation
shall be valid for a period of five (5) years.
(1) Veterinary medicinal products, investigational Authorisation
for research and
veterinary medicinal products and active substances shall not be used development
for research and development purposes unless the Director grants such purposes.
authorisation to the applicant.
(2) The applicants requesting authorisation to use veterinary
medicinal products, investigational veterinary medicinal products and,
or active substances for research and development purposes shall
submit an application in the form provided by the Director before the
activity takes place and shall pay the relevant fee.
(3) Veterinary medicinal products authorised in accordance
with this regulation may be exempt from the requirements established
by Articles 5, 88 and 99 of Regulation (EU) 2019/6.
(4) Active substances authorised in accordance with this
regulation may be exempted from the requirements established by
Article 95 of Regulation (EU) 2019/6.
(5) The authorisation granted in accordance with this regulation
shall be valid for a period of three (3) years.
(6)
An authorisation in accordance with this regulation shall be
granted without prejudice to any authorisation, licence or permit that
the applicant may need to obtain from another entity in order to engage
in the research activity involving veterinary medicinal product,
investigational veterinary medicinal products or active substances.
(7) The Director may establish, amend, add or remove any
terms and conditions pertaining to the authorisation that he may deem
fit in light of scientific advancements or new information that may
arise, from time to time.
(8) If applicable, the holder of the authorisation in accordance
with this regulation shall administer the product to the test animal after
obtaining prior authorisation from the relevant entity and only in
accordance with the terms and conditions set out in the Animal
Welfare Act and the Protection of Animals used for Scientific Purposes
Regulations.
(9) Unless a withdrawal period is determined, test animals
administered veterinary medicinal products, investigational veterinary
medicinal products and active substances authorised in accordance
with this regulation shall be excluded permanently from the food
chain.
(10) The holder of an authorisation in accordance with this
regulation shall notify the Director within fifteen (15) days of
becoming aware of any adverse reactions on the animal or on the
person administering the products or substances in terms of this
regulation
Provided that the records provided for in this regulation
shall be kept by the holder of an authorisation in accordance with this
regulation for a period of five (5) years and shall be made available to
the Director upon his request.
(11) The Director may carry out inspections on the premises and
the activities being carried out on the premises by the holder of the
authorisation.
(1) Veterinary medicinal products may be exempted from
the requirements provided for in Articles 5, 88 and 99 of Regulation
(EU) 2019/6 when the products are acquired from a Member State or
imported for personal use provided that all the following conditions are
fulfilled
(a)
the products shall not be sold or re-sold;
(b) the products shall not be transferred to other third
parties unless such transfer is notified to the Director;
(c) the quantity of products obtained shall be proportional
to the dosage regime of the condition it will be used for;
(d) the quantity of products which is allowed entry in the
territory of Malta shall cover the period indicated as the duration
of treatment in the product’s specifications or on the veterinary
prescription. However, products intended to be used for recurrent
or chronic conditions may be allowed entry in the territory of
Malta several times a year, provided that cogent evidence that
demonstrates the benefits obtained by the regular use of the
products can be provided;
(e)
a veterinary prescription shall be provided for
products classified as requiring such a prescription in the country
from where they are obtained, or for similar veterinary medicinal
products in the territory of Malta
Provided that the Director may still require the
veterinary prescription when the products are classified as not
requiring a veterinary prescription in the country from where
they are obtained;
(f) only products that do not contain animal by-products
which are derived from high-risk areas where certain diseases
may be, or suspected to be, present or prevalent, shall be
obtained;
(g) only products that do not contain ingredients which
are classified as illegal in territory of Malta and which do not
have banned indications in the territory of Malta shall be
obtained;
(h) only appropriately labelled products which give clear
indication of the nature of the ingredients thereof shall be
obtained;
(i) food producing animals administered with the
veterinary medicinal products authorised in accordance with this
regulation may only be consumed by the individual getting the
veterinary medicinal products, or by other consenting persons of
the same household. The appropriate withdrawal period shall
apply, where applicable;
(j) before a decision on antimicrobial veterinary
medicinal products and products that have a hormonal activity is
taken, a risk assessment shall be prepared by the Director in a
timely manner; and
(k) the Director’s decision shall be without prejudice to
any license or permit that the individual getting the veterinary
medicinal products may need to obtain under other regulations or
rules.
(2) This regulation shall not be applicable to live or attenuated
immunological veterinary medicinal products, psychotropic drugs,
narcotic drugs for all animals and, in the case of food producing
animals, also the substances listed in Group A in Schedule I of the
Measures to monitor certain Substances and Residues thereof in Live
Animals and Animal Products Rules and the substances listed in Table
2 of Commission Regulation (EU) No 37/2010 of 22 December 2009
on pharmacologically active substances and their classification
regarding maximum residue limits in foodstuffs of animal origin.
(3) The Director may release, retain or destroy any veterinary
medicinal products alone or in feed, active substances or other products
intended to be administered to or on animals or given as feed or with
feed or water if and when these products are intercepted at the various
entry control points throughout the territory of Malta, or in any
establishments under his control.
(4) Any expense incurred for the release, retention or
destruction of veterinary medicinal products alone or in feed, active
substances or other products intended to be administered to, or on
animals or given as feed or with feed or water, shall be payable by the
person getting the products as determined by the Director.
(5) Pursuant to sub-regulation (3), the Director may keep a
record of all instances of release, retention or destruction. These
records shall be kept by the Director for a period of not less than fifteen
(15) years.
(6) The Director may issue a list with the requirements needed
for obtaining veterinary medicinal products in accordance with this
regulation through a notice in the Gazette
Provided that the provisions of this regulation shall also
apply to veterinary medicinal products that are brought in the territory
of Malta as a donation for use on animals kept in approved sanctuaries
subject to the donations
Provided further that the Director shall be notified of such
request with the name, quantity and nature of the products, the names
and addresses of the donor, the recipient and the animal sanctuaries
involved.
(1) Before the placing on the market of any veterinary Registration in
accordance with
medicinal product as established by Article 116 of Regulation (EU) Article 116 of
2019/6, a person shall register every veterinary medicinal product with Regulation
2019/6.
the Director in the manner provided by him and shall pay the relevant
(2)
Before approving the registration, the Director may
(a) request the competent authority in the country of
source to furnish a copy of the current marketing authorisation;
(b) ensure that the entity applying for a registration in
accordance with Article 116 of Regulation (EU) 2019/6 is a
legally established company in the European Union or European
Economic Area;
(c) notify the marketing authorisation holder of his
intention to grant a registration in accordance with Article 116 of
Regulation (EU) 2019/6 when the applicant is not the same entity
as the marketing authorisation holder in the country of source;
(d) request the applicant to furnish a copy of the current
marketing authorisation
Provided that when it is not possible for the applicant
to provide a copy of the current marketing authorisation, he shall
be required to provide alternative evidence that the product is
being marketed in the country of source;
(e) request from the applicant data on the impact of the
product on the environment in the territory of Malta;
(f) request the applicant to furnish a letter of access
issued by the market authorisation holder granting him the use of
the marketing authorisation for the purposes of Article 116 of
Regulation (EU) 2019/6
Provided that when it is not possible for the applicant
to obtain a letter of access from the market authorisation holder,
the applicant may be requested by the Director to provide
evidence that due diligence has been exercised to ensure that the
veterinary medicinal products were obtained from a duly
authorised supplier of veterinary medicinal products in the
country of source; and
(g) ensure that the applicant has a system in place for the
recording and investigation of adverse drug reactions and defects
in a batch or veterinary medicinal product.
(3) After registration in accordance with this regulation, the
registration holder shall ensure that
(a) the veterinary medicinal product is kept in line with
the marketing authorisation issued in the country of source for as
long as the registration remains valid;
(b) the Director is notified of any variation to the terms of
the marketing authorisation approved in the country of source
that affects the summary of the products’ characteristics, the
package leaflet, the packaging, the labelling and any change in
administrative details that may have been made after the original
registration;
(c) any action relating to adverse drug reaction and, or a
product or batch recall shall be implemented without delay; and
(d) he is responsible for the requirements in paragraph
(c), or appoints another person for such purpose.
(4) By way of derogation from Article 2(1) and (2) of the
Regulation (EU) 2019/6, only Articles 57, 94, 117, 119, 123 and 134 of
Regulation (EU) 2019/6 shall apply to veterinary medicinal products
registered in accordance with Article 116 of Regulation (EU) 2019/6.
(5) The registration granted in accordance with this regulation
shall be valid for a period of three (3) years.
(1) A veterinary medicinal product shall not be procured
from another Member State or imported by veterinary surgeons before
the Director grants the necessary authorisation in accordance with
Articles 110 (2) and (3), 112, 113 and, or 114 of Regulation (EU)
2019/6.
(2) Veterinary surgeons shall apply in the manner provided by
the Director to obtain an authorisation for procuring a veterinary
medicinal product from another Member State or for the importation of
veterinary medicinal products in accordance with Articles 110 (2) and
(3), 112, 113 or 114 of Regulation (EU) 2019/6 and shall pay the
relevant fee.
(3) The authorisation granted in accordance with this regulation
shall be valid for a period of one (1) year.
(4) Veterinary surgeons shall keep adequate records of the
treatment given with the veterinary medicinal products authorised in
accordance with this regulation for a period of not less than five (5)
years and shall be made readily available to the Director upon his
request.
(5) The records provided for in this regulation shall include the
identification, including the target species, of the animal or group of
animals, the date of supply, the dosage, the administration instructions
and the withdrawal period assigned, if applicable.
(6) For the purposes of this regulation, the activity undertaken
by the veterinary surgeons shall be excluded from the provisions of
Articles 88 and 99 of Regulation (EU) 2019/6.
(1) For the purposes of Article 86 of Regulation (EU) Registration of
homeopathic
2019/6, a person shall submit a request in the manner indicated by the veterinary
Director for each homeopathic veterinary medicinal product that he medicinal
products.
intends to register and place on the market and shall pay the relevant
fee.
(2) The registration granted in accordance with this regulation
shall be valid for a period of five (5) years.
(1) For the purposes of Article 102 of Regulation (EU) Parallel trade.
2019/6, wholesale distributors shall submit a request in the manner
indicated by the Director for the registration of each veterinary
medicinal product intended for parallel trade and shall pay the relevant
fee.
(2) The registration granted in accordance with this regulation
shall be valid for a period of five (5) years.
(1) For the purposes of these regulations, the manufacture
of active substances shall include both total and partial manufacture or
importation of an active substance, and the various processes of
dividing up, packaging or presentation prior to their incorporation into
a veterinary medicinal product, including repackaging or re-labelling,
as are carried out by a distributor.
(2) For the purposes of Article 89 of Regulation (EU) 2019/6,
the applicants shall submit an application in the manner provided by
the Director to obtain the manufacturing authorisation referred to in
Article 88(1) of Regulation (EU) 2019/6 and shall pay the relevant
fees.
(3) A manufacturing authorisation shall not be required for
preparation, division, changes in packaging or presentation where
these processes are carried out solely for retail directly to the public by
pharmacists in veterinary pharmacies, or by other persons legally
authorised to supply veterinary medicinal products to the public.
(4) The manufacturing authorisation shall only be granted by
the Director when the requirements provided for in Article 89 of
Regulation (EU) 2019/6 are satisfied.
(5) The Director may, upon a request by the holder of
authorisation for a change in the manufacturing authorisation, vary the
condition of the authorisation if he is satisfied that such change will not
adversely affect the standard of good practice in manufacture as may
be prescribed.
(6) For the purposes of Article 133 of Regulation (EU) 2019/6
and when the Director considers that circumstances may exist which
necessitate the consideration of whether the authorisation should be
varied, suspended or revoked, the Director may serve on the holder of a
manufacturing authorisation a notice requiring him, within such period
as may be specified in such notice, to obtain any information specified
in the notice.
(7) The Director may, at his own discretion, suspend, revoke or
vary the conditions of a manufacturing authorisation if
(a) the information stated in the application on which the
authorisation was granted was false or incomplete in an essential
manner;
(b) a material change of circumstances has occurred in
relation to any of such information;
(c) any
condition
of
the
authorisation
has
been
contravened;
(d) the requirements in relation to the authorisation as
established by these regulations and Regulation (EU) 2019/6
have not been complied with;
(e) the processes of manufacture or assembly of a
veterinary medicinal product are carried out in a manner that is
not in compliance with the provisions of the marketing
authorisation of that veterinary medicinal product;
(f) the conditions for good manufacturing practice are
not being complied with;
(g) there exists the sale and processing of active
substance and veterinary medicinal products under unsanitary
conditions or leading to adulteration; and
(h)
there occurs any of the other circumstances
established under these regulations.
(8) The Director may carry out regular inspections to ensure
that the requirements established by these regulations in relation to the
manufacture, assembly or modification of a veterinary medicinal
product or active substance are complied with.
(9) With respect to the manufacture of veterinary medicinal
products and active substance, the Director may
(a) inspect the manufacturing establishment and any
other premises at any reasonable time;
(b)
examine any relevant document;
(c) take any sample deemed necessary and if necessary,
submit it to designated laboratories for testing;
(d) open or, and examine or, and seize any article
believed to be in violation of these regulations or for obtaining
evidence;
(e) draw up a report of the findings and communicate the
contents of such report to the manufacturing authorisation holder
or the applicant for a manufacturing authorisation and to the
qualified person in relation to such inspection;
(f) carry out any other activity as he may deem
appropriate for the proper execution of his duties and
responsibilities as provided by these regulations;
(g) produce, upon request by the inspected part, the
designated document containing information on the legal basis
and scope of the inspection and the identification of the
inspector;
(h) at the time of the inspection draw up a list of
deficiencies that may have been identified and shall sign this list,
and such list shall be countersigned by the holder of the
authorisation or his legal representative; and
(i)
draw up a report of the inspection within thirty (30)
working days of the inspection and forward a copy of such report
to the holder of the authorisation.
(10) Except in urgent cases, an inspection shall be carried out in
the presence of a qualified person responsible for manufacturing and
batch release referred to in Article 97 of Regulation (EU) 2019/6, or
his representative.
(11) Subject to the provisions of these regulations, every
authorisation shall, unless previously renewed or revoked, continue to
be valid until such time as it is renewed by the Director following an
inspection.
(12) Unless otherwise determined by the Director based on the
conclusions of an inspection, the authorisation shall be valid for a
period of three (3) years.
(13) Following an inspection the Director may renew the
authorisation, with or without modifications, for such a further period
as specified.
(14) The holder of the manufacturing authorisation, or the
manufacturer of active substance shall
(a)
verify the authenticity and quality of the excipients;
(b) keep a record of all suspected adverse reactions and
adverse reactions on humans relating to the use of veterinary
medicinal products that are brought to his attention and report
them promptly to the Director in no later than fifteen days (15)
following receipt of the information;
(c) implement a system for recording and reviewing
complaints together with an effective system for recalling
promptly and at any time the veterinary medicinal products or the
active substance in the distribution network;
(d) record and investigate any complaint concerning
quality defects; and
(e) perform other responsibilities as may be established
by the Director from time to time.
(15) Manufacturing authorisation holders shall be regarded as
producers and therefore shall be held liable for damages in cases and
under the conditions set forth in the Consumer Affairs Act.
(16) The Director may require from the applicant further
information concerning the particulars supplied pursuant to Article
89(2) of Regulation (EU) 2019/6 and the qualified person referred to in
Article 97 of Regulation (EU) 2019/6
Provided that before the applicant provides the requested
information, the manufacturing authorisation shall be suspended.
(1) When more than one (1) qualified person is Qualified
person.
nominated in accordance with Article 97 of Regulation (EU) 2019/6,
the application shall clearly indicate the specific responsibilities of
each person
Provided that the qualified person may nominate another
person similarly qualified to act as his representative and shall notify
the Director of such nomination within one (1) working day.
(2) A person carrying out duties of a qualified person before the
coming into force of these regulations shall continue to carry out his
duties without the requirements of the provisions of Article 97(2)(3) of
Regulation (EU) 2019/6.
(3) If the qualified person started following a course prior to the
date on which these regulations became applicable, he may be
considered as qualified to carry out the duties thereof
Provided that he shall have been previously engaged in one
(1) or more of the following activities for at least two (2) years before
the date on which these regulations became applicable
(a) in one (1) or more undertakings with a manufacturing
authorisation and production supervision; and, or
(b) qualitative and quantitative analysis of active
substances, and the necessary testing and checking to ensure the
quality of veterinary medicinal products
Provided further that if the person concerned has acquired
the practical experience referred to before the date of the coming into
force of these regulations, he shall complete a further one (1) year’s
practical experience in accordance with the conditions referred to in
sub-regulation (1) immediately before he engages in such activities.
(4) The qualified person shall ensure that standards of good
practice in manufacturing are complied with at all times.
(1) When veterinary medicinal products are in transit for
the sole purpose of export and without them being placed on the
European Union market, the provisions of Article 88 of Regulation
(EU) 2019/6 shall apply, even though the product remains intact and
no manufacturing activities are carried out
Provided that such products may be exempted from the
provisions of Article 88 of Regulation (EU) 2019/6 when the transit is
for the sole purpose of re-export, is affected within the freeport, free
trade zones or customs tax warehouses. However, in such instances the
wholesale distribution authorisation provided for in Article 99 of
Regulation (EU) 2019/6 shall nonetheless be required by the company
engaging in the process.
(2) In cases where manufacturing activity in relation to the
products in transit for the sole purpose of export is carried out, the
manufacturing authorisation provided for in Article 88 of Regulation
(EU) 2019/6 shall be required, even if the operations are affected
within the freeport, free trade zones or customs tax warehouses.
(3)
The veterinary medicinal products which are in transit for
the sole purpose of export which qualify for the exemption provided
for in this regulation may be also exempted from the provisions of
Article 5 of Regulation (EU) 2019/6.
(4) The Director shall be notified by the wholesale distributor
in the manner indicated by the Director if such an activity is ever
conducted.
The retail supply of veterinary medicinal products shall be Retail supply of
veterinary
conducted only from or through licensed veterinary pharmacies in the medicinal
territory of Malta, licensed veterinary establishments, the products.
establishments provided for in regulation 18(2) and by veterinary
surgeons in relation to animals under their care, in the course of their
professional visits or visits by clients.
(1) Veterinary medicinal products may only be dispensed Dispensing.
from the premises and persons provided for in regulation 18.
(2) A veterinary surgeon may dispense veterinary medicinal
products during his professional visits or when clients visit him
Provided that the veterinary surgeon shall supply the
quantities of veterinary medicinal products only for treatments to
animals under his care. If the type of the packaging is such that the
veterinary surgeon cannot supply lesser quantities thereof, the
veterinary surgeon may supply the animal owner and, or the keeper
and, or the carer with the quantities needed for the full treatment of the
condition.
(3) In any doubtful situation and within the limits of his
responsibilities, when dispensing veterinary medicinal products, the
dispenser shall be satisfied that the person who will use the product is
competent to do so safely and intends to use it for a purpose for which
it is authorised or indicated by the veterinary surgeon.
(4) When dispensing veterinary medicinal product, the
dispenser shall advise the receiver of the product on the dosing, safe
administration of the product and on any warnings or contra-
indications on the label or package leaflet, including information on
any applicable withdrawal periods.
(5) The dispenser shall provide to the Director any information
about veterinary medicinal products, including data on sales and use of
veterinary medicinal products upon his request.
(6) When dispensing veterinary medicinal products and
medicinal products for human use containing antimicrobials, the
dispenser shall be satisfied that all necessary precautions have been
taken to minimise the risks of antimicrobial resistance, in particular the
use of critically important antimicrobials.
(7) If the dispenser is not the veterinary surgeon issuing the
veterinary prescription and the dispenser has concerns about the
veterinary prescription presented to him, he shall resolve them with the
prescribing veterinary surgeon before dispensing the product.
(8) If a veterinary medicinal product is supplied in a container
other than that specified in the marketing authorisation, the dispenser
shall ensure that the container is suitably labelled and shall supply
sufficient written information.
(9) The dispenser shall be present when a veterinary medicinal
product is dispensed unless
(a) each transaction is authorised individually before the
product is supplied; and
(b) the dispenser is satisfied that the person dispensing it
over is competent to do so.
(10) The Director may request the dispenser to provide any
samples of the veterinary medicinal products.
(1) No person shall prescribe veterinary medicinal
products or medicinal products for human use unless that person is a
veterinary surgeon.
(2) The prescribing of veterinary medicinal products or
medicinal products for human use shall be made only on the veterinary
prescription provided for in regulation 31.
(3) A veterinary surgeon may only prescribe veterinary
medicinal products or medicinal products for human use if that
veterinary surgeon has examined those particular animals and he shall
accept clinical responsibility for the treatment of the animals under his
care.
(4) Veterinary medicinal products or medicinal products for
human use may not be used for more than one (1) treatment under the
same veterinary prescription.
(5) Before prescribing veterinary medicinal products or
medicinal products to be administered to animals which require a
veterinary prescription, a veterinary surgeon shall carry out a clinical
assessment of the animal under his care.
(6) Before prescribing a veterinary medicinal products or
medicinal products for human use, the veterinary surgeon shall be
satisfied that
(a) the use of the veterinary medicinal products or
medicinal products for human use is justified for the species
concerned on veterinary grounds;
(b) the administration of the veterinary medicinal
products or medicinal products for human use is not incompatible
with a previous treatment or use and that there is no contra-
indication or interaction where several veterinary medicinal
products and medicinal products for human use are used;
(c) the veterinary medicinal products or medicinal
products for human use are prescribed only in such quantities as
are necessary for the purpose of the treatment; and
(d) all necessary precautions shall be taken to minimise
the risks of antimicrobial resistance and that the prudent use of
veterinary medicinal products or medicinal products for human
use containing antimicrobials have been taken in consideration,
in particular where critically important antimicrobials are being
used.
(7) Within the limits of his responsibility, when prescribing
veterinary medicinal products or medicinal products for human use, a
veterinary surgeon shall be satisfied that the person who will
administer the products on the respective animal is competent to do so
safely and intends to use it for a purpose for which it is authorised or
directed by the veterinary surgeon.
(8) When prescribing veterinary medicinal products or
medicinal products for human use containing antimicrobials, a
veterinary surgeon shall consider the guidelines as issued by the
Director and other relevant national, European and international
organisations with regard to critically important antimicrobials.
(9)
When preparing a veterinary prescription, the prescribing
veterinary surgeon shall advise the receiver of the veterinary
prescription on the safe administration of the veterinary medicinal
product or medicinal product for human use and on any warning or
contra-indication associated with their use.
(1) In the territory of Malta there shall be the following
four (4) distribution categories of veterinary medicinal product
(a) prescription-only-medicine, veterinary surgeon and
pharmacist, abbreviated to "POM-VP";
(b) prescription-only-medicine,
veterinary
surgeon,
abbreviated to "POM-V";
(c)
over-the-counter-medicine, abbreviated to "OTC";
and
(d)
general sales, abbreviated to "GS".
(2) The supply of veterinary medicinal products for each
distribution category shall be made as follows
(a) POM-VP shall only be prescribed and, or dispensed
by a veterinary surgeon or dispensed by a pharmacist according
to the terms of a veterinary prescription. The premises from
where, or through which, these veterinary medicinal products
may be supplied to the public shall be licensed veterinary
pharmacies and licensed veterinary establishments;
(b) POM-V shall only be prescribed, dispensed and
administered by a veterinary surgeon. The premises from where,
or through which, these veterinary medicinal products may be
supplied shall be licensed veterinary pharmacies and licensed
veterinary establishments;
(c) OTC may be dispensed without a veterinary
prescription. The persons who may dispense these veterinary
medicinal products shall be veterinary surgeons, pharmacists and
suitably learned persons under the supervision of a pharmacist or
a veterinary surgeon. The premises from where, or through
which, these veterinary medicinal products may be supplied to
the public shall be licensed veterinary pharmacies and licensed
veterinary establishments;
(d)
GS
may
be
dispensed
without
a
veterinary
prescription. The persons who may dispense these veterinary
medicinal products shall be veterinary surgeons, pharmacists and
suitably learned persons. Veterinary medicinal products that fall
under this category may be supplied to the public from, or
through, licensed veterinary pharmacies, licensed veterinary
establishments, registered pet shops, registered shops that retail
animal care products and approved feed business operators where
medicated feeds are manufactured, sold or traded
Provided that, a person carrying out the activities of the
suitably learned person on the date on which his qualifications of a
suitably learned person are published shall be eligible to continue to
engage in such activities.
(3) The Director shall determine the distribution category of
veterinary medicinal products when processing application forms for
the authorisation or registration thereof
Provided that this shall not preclude the Director from
changing the distribution category of any veterinary medicinal product
at any stage after authorisation or registration has been granted.
(4) The marketing authorisation holders and holders of
registration in accordance with Article 116 of Regulation (EU) 2019/6
may request the Director to amend the distribution category previously
assigned.
(5) When determining the distribution category of veterinary
medicinal products, the Director may seek the advice from suitable
expert committees and may take in consideration the guidelines of
other national, European and international relevant bodies.
(6) Different pack sizes of the same marketing authorisation
may be assigned a different distribution category.
(7) The Director may issue guidelines on the criteria based on
Article 34 of Regulation (EU) 2019/6 for the categorisation of a
veterinary medicinal product.
(8) The holders of a wholesale distribution authorisation shall
distribute veterinary medicinal products only to those premises
authorised to retail veterinary medicinal products and shall distribute
only the category or categories of veterinary medicinal products that
are authorised to be retailed from each type of premises in accordance
with these regulations.
(1)
Any advertising of a veterinary medicinal product
shall include
(a)
the trade name;
(b)
a list of active ingredients;
(c)
the pharmaceutical form;
(d)
the major indications for use;
(e)
the dosage and method of use;
(f) side
effects,
warnings,
precautions
and
contraindications;
(g) the name and address of the marketing authorisation
holder; and
(h) any research and, or publications on the use of the
active substance.
(2) All the information contained in the documentation referred
to in this regulation shall be accurate, up-to-date, verifiable and
sufficiently complete to enable the recipient to form his own opinion of
the therapeutic value of the veterinary medicinal product concerned.
(3) Quotations as well as tables and other illustrative matter
taken from scientific works for use in the documentation provided for
in this regulation shall be faithfully reproduced.
(4)
The person who advertises veterinary medicinal products
(a) keep for a period of not less than five (5) years a
sample of all advertisements emanating from his undertaking
together with a statement indicating to whom the advert is
addressed, the method of dissemination and the date of first
dissemination; and
(b) ensure that any decision taken and any conditions
condition imposed by the Director are immediately and fully
complied with.
(5) The Director may request any of the information provided
for in this regulation at any time.
(1) For the purposes of Article 119(1) and (9) of Samples or
demonstration
Regulation (EU) 2019/6, veterinary medicinal products may be packs.
exempted from the requirements established by Article 5 of Regulation
(EU) 2019/6 if these are intended to be used as samples and, or as
demonstration packs that are given directly to veterinary surgeons or
other persons who are allowed to supply veterinary medicinal products
during sponsored events by pharmaceutical companies or during
professional visits to those persons who are authorised to prescribe or
dispense veterinary medicinal products
Provided that this exemption shall be granted by the
Director following a request from the wholesale distributor of
veterinary medicinal products in the manner indicated by the Director
before the activity takes place, and the exemption shall not be used
before the product has been registered.
(2)
The Director shall only register the product when
(a) the veterinary medicinal products are labelled with
the following words "Free sample - Not for sale" or
"Demonstration pack - Not for sale", as the case may be;
(b) each sample or demonstration pack shall not be bigger
than its smallest presentation on the market;
(c) each sample or demonstration pack shall be
accompanied by a copy of the summary of product
characteristics;
(d) veterinary
medicinal
products
containing
psychotropic or narcotic drugs cannot be distributed as samples
or demonstration packs;
(e) starter packs shall not be regarded as samples and
shall not be labelled as such;
(f) during visits by sales representatives, the persons
visited should be given information about the use of the
veterinary medicinal products, with particular reference to any
adverse reaction;
(g)
the information provided with the samples or
demonstration packs shall not be promotional in nature;
(h) the applicant shall be a holder of a wholesale
distribution authorisation; and
(i) the validity period of the authorisation shall be one
(1) year from the first consignment thereof.
(3) If any veterinary medicinal product registered in accordance
with this regulation is administered on a food producing animal, that
animal shall be excluded permanently from the food chain.
It shall not be lawful for a person authorised to distribute or
retail veterinary medicinal products to enter into any form of
contractual agreement with animal keepers and, or owners and, or
carers in order to supply to them veterinary medicinal products.
(1) Only authorised or registered veterinary medicinal
products shall be wholesale distributed in the territory of Malta.
(2) Persons may only apply for a wholesale distribution
authorisation of veterinary medicinal products if they are established in
the territory of Malta and have a permanent address
Provided that, this regulation shall not be applicable to
small quantities of veterinary medicinal products supplied from one (1)
retailer to another established in the territory of Malta in accordance
with a decision which shall be stipulated by the Director.
(1) An application for the grant of a wholesale
distribution authorisation provided for in Article 99(1) of Regulation
(EU) 2019/6 shall be made in the manner provided by the Director, and
shall include such information, documents and other material as
provided for by these regulations and Regulation (EU) 2019/6.
(2) An application for the grant of a wholesale distribution
authorisation shall include the following
(a)
the name and address of the applicant;
(b) the name of the responsible person provided for in
Article 100(2)(a) of Regulation 2019/6;
(c) the address of the premises that is to be used for the
purpose of wholesale distribution;
(d) other relevant permits for the premises that is to be
used for the purpose of wholesale distribution from other Maltese
regulatory entities;
(e) a licence, permit or equivalent document from the
financial services or an equivalent authority if the applicant is a
limited liability company;
(f) the equipment and control facilities as may be
required in these regulations;
(g) information, documentation or evidence to prove that
the premises is suitable and adequate, and that there are suitable
facilities, installations and equipment so as to ensure proper
conservation and distribution of veterinary medicinal products as
determined by the Director;
(h) the pharmaceutical forms of the products to be
distributed, in particular any sterile product and product requiring
storage below eight Centigrade (8º), if applicable;
(i) the details of narcotic or psychotropic drugs, blood, or
veterinary immunological medicinal products;
(j) the approval from the authority in the territory of
Malta responsible for planning and building permits, if
applicable; and
(k) the activities related with the wholesale distribution
of veterinary medicinal products intended to be carried out by the
applicant
Provided that the Director may request from the applicant
any other relevant information or additional document, which is
deemed necessary for the purpose of these regulations at any time.
(3) The premises used for the wholesale distribution of
veterinary medicinal products shall not be interconnected with other
premises which are used for other commercial activities or for
habitation
Provided that, interconnection with any other premises
which is used for other commercial activities or for habitation may be
allowed when the scale of activities and the commercial turnover of
veterinary medicinal products may be reasonably expected to be below
a certain threshold established by the Director by means of a notice in
the Gazette. In such cases, the physical connection between the
premises shall be kept to a minimum whilst the different areas shall be
clearly demarcated and properly marked so that a visible distinction
can be made clearly and unequivocally
Provided further that, the provisions of this sub-regulation
shall not apply in respect of existing premises before the coming into
force of these regulations and which cannot be structurally altered as to
comply with the said provisions.
(4) The Director may revoke a wholesale distributor
authorisation granted through such an exemption at any time.
(1) No person shall act as a wholesale distributor of
veterinary medicinal products unless a wholesale distribution
authorisation is issued by the Director.
(2) The Director shall carry out inspections at the premises
indicated in the application and shall not issue the authorisation until
he is satisfied that such premises is in conformity with the
requirements established in Regulation (EU) 2019/6 and these
regulations.
(3) The authorisation granted shall include the premises and the
applicable activities.
(4) A person who intends to acquire a wholesale distribution
authorisation shall apply with the Director by means of the application
form issued by the said Director and shall pay the applicable fee.
(5) All the premises, equipment and documents used by the
wholesale distributor shall be readily accessible at all reasonable times
for inspection by the Director.
(1) The wholesale distributor of veterinary medicinal
products shall
(a) comply with the requirements as stipulated by Article
101 of Regulation (EU) 2019/6;
(b) immediately inform the Director of any change in the
details given in the original application within one (1) working
day of the said change;
(c) provide the Director access to his premises at any
reasonable time to carry out inspections as necessary;
(d) provide any sample of the veterinary medicinal
products which are distributed or were distributed or intended to
be distributed or found in the authorized premises at the request
of the Director;
(e) provide any information and document about
veterinary medicinal products, including data on sales,
distribution and use of veterinary medicinal products as
requested by the Director;
(f) inform the Director of any intention to relocate the
premises authorised for the wholesale distribution of veterinary
medicinal products three (3) months prior relocation and shall
apply for a new authorisation in accordance with regulation 23;
and
(g) carry out any other responsibility as may be
established from time to time by the Director.
(2) When the veterinary medicinal product is obtained from the
manufacturer or importer, the wholesale distributor shall verify that the
manufacturer or importer holds a valid manufacturing authorisation.
(3) When the veterinary medicinal product is obtained through
brokering, the wholesale distributor shall verify that the broker
satisfies the requirements set out in these regulations and that he has a
valid registration for the activity of brokering.
(4) When the veterinary medicinal product is obtained from
another wholesale distributor of veterinary medicinal products, the
wholesale distributor shall verify that the other wholesale distributor of
veterinary medicinal products holds a valid wholesale distribution
authorisation.
(5) When distributing veterinary medicinal product to persons
entitled to retail veterinary medicinal products in the territory of Malta
the wholesale distributor shall keep record of at least the name of
veterinary medicinal product, name of recipient, pharmaceutical form,
batch number, expiry date and quantities supplied in respect of each
transaction.
(6) A wholesale distributor shall exercise all necessary
precautions when veterinary medicinal products are received from a
third country but not imported for the sole purpose of export, in order
to ensure that these veterinary medicinal products do not in any way
end up on any Member State market.
(7) The Director may request the wholesale distributor to
provide a letter of access issued by the marketing authorisation holder
granting the wholesale distribution authorisation holder the use of such
marketing authorisation in respect of each veterinary medicinal
product he distributes and which is obtained directly from the
marketing authorisation holder or his legal representative.
(1) Every authorisation granted under these regulations
shall, unless previously renewed or revoked remain valid until such
time as it is renewed by the Director.
(2) Unless otherwise determined by the Director based on the
conclusions of an inspection, the authorisation shall be valid for a
period of three (3) years.
(3) The Director may renew the authorisation with or without
modifications for such a further period as specified by the Director, or
refuse to renew the authorisation
Provided that in the case that the authorisation is not
renewed, the Director shall stipulate corrective measures as necessary,
and he may suspend the authorisation until it is confirmed that the
holder of the authorisation is in compliance with these regulations and
Regulation (EU) 2019/6.
(4) The Director may suspend or revoke the authorisation
granted under these regulations for such period as it may be determined
in any of the following instances
(a) where the information stated in the application on
which the authorisation was issued was false or incomplete in a
particular detail;
(b) where a material change of circumstance has occurred
in relation to any of that information;
(c) where any condition of the authorisation has been
contravened;
(d) where the requirements in relation to the authorisation
as provided for by these regulations and Regulation (EU) 2019/6
have not been complied with; and
(e) where conditions of good practice in wholesale
distribution, particularly those established by the Commission in
the implementation of Regulation (EU) 2021/1248 are not being
complied with
Provided that the Director may revoke or suspend the
authorisation for any other matter that he deems appropriate.
(1) The responsible person shall be a pharmacist enlisted Duties of the
responsible
in the Register of Pharmacists in terms of article 17 of the Health Care person.
Professions Act.
(2)
The responsible person shall
(a) ensure that the wholesale distribution authorisation
conditions are adhered to;
(b) be permanently and continuously at the disposal of
the holder of the wholesale authorisation;
(c) nominate, if necessary, another person to act as his
representative and inform the Director of such nomination within
one (1) working day from date of nomination;
(d) inform the Director within one (1) working day in the
case that another representative be replacing the previous
representative temporarily or permanently;
(e) not abandon his duties without giving prior notice in
writing to the Director and to the wholesale distributor at least
two (2) weeks in advance;
(f) have in place a contact number which is available
twenty-four (24) hours a day and seven (7) days a week in case of
emergencies which shall also be provided to the Director; and
(g) upon request by the Director, provide any data in his
possession relating to the importation, sale, distribution, use and
administration of any type of veterinary medicinal product.
(1) Without prejudice to any provision of these Other medicinal
products.
regulations, the Director may establish additional requirements for the
wholesale distribution of the following veterinary medicinal products
and publish them in the Gazette
(a) veterinary medicinal products containing strong
sedatives, narcotic drugs or psychotropic drugs;
(b)
veterinary medicinal products used for euthanasia;
(c)
veterinary medicinal products derived from blood;
(d)
immunological veterinary medicinal products;
(e) such other veterinary medicinal products or class or
classes of veterinary medicinal products as the Minister may
prescribe; and
(f) veterinary
medicinal
products
containing
antimicrobials, in particular those that are deemed critical for
human health.
(2) Without prejudice to any provision of these regulations, the
Director shall take the necessary measures in order to prevent
veterinary medicinal products that are introduced into the European
Union but which are not intended to be placed on the market of the
European Union from entering into circulation if there are sufficient
grounds to suspect that those products are falsified. These measures
shall include the application of these regulations to warehouses
situated in the free port, free trade zones or customs tax warehouses
authorized to store veterinary medicinal products. These measures may
be issued in the Gazette through a notice.
(3) When the Director has valid reason to believe that
circumstances may exist which would render necessary the
consideration of whether the wholesale distribution authorisation
should be varied, suspended or revoked, the Director may serve the
holder a notice requiring him, within such period as may be specified
in the notice, to provide any information specified in the notice.
(1) Any person intending to engage in the brokering of
veterinary medicinal products shall have a permanent address in the
territory of Malta and shall register his activity with the Director before
the activity takes place.
(2) The person intending to engage in the brokering of
veterinary medicinal products shall send a request to the Director in the
in the manner indicated by the Director to register his activity, and the
request shall include
(a) the name of the applicant and, if applicable, the
corporate name;
(b)
the permanent address in the territory of Malta;
(c)
the contact details of the applicant; and
(d)
the payment of the relevant fee
Provided that the Director may request, from time to time,
any other relevant information or additional document which he may
deem necessary for the purpose of the registration.
(3) The Director shall process the request for registration of a
broker within ninety (90) days of receipt of the request which shall be
suspended in cases where the applicant is requested to provide
additional data.
(4) The Director may carry out an inspection at the permanent
address of the applicant before registering the activity of the applicant
to ensure accurate identification and location, and that the applicant
has the necessary means to conduct the activity and is in compliance
with these regulations.
(5) Where the Director notifies that an inspection shall be
carried out, the activity shall not begin before the Director has notified
that the activity may start. In such a case, the Director shall carry out
the inspection and communicate to the broker the results of the
inspection within ninety (90) days of the notification of his intention to
carry out the inspection. When within ninety (90) days of receipt of the
request the Director has not notified that an inspection shall be carried
out, the activity may start.
(6)
The broker shall
(a) inform the Director of any change in the details given
in the original registration within one (1) working day;
(b) provide the Director access to his permanent address
at any reasonable time;
(c)
maintain records for any dealings in veterinary
medicinal products as may be provided for by these regulations,
and have such records readily available for inspection by the
Director for a period of not less than five (5) years;
(d) provide any information about the brokering
veterinary medicinal products, including information about the
amounts and identity of veterinary medicinal products brokered;
(e) abide by other responsibilities as may be established
from time to time by the Director; and
(f) informs the Director and, where applicable, other
related parties, of veterinary medicinal products he suspects to be
falsified.
(7) Unless otherwise determined by the Director, the
registration granted in accordance with this regulation shall be valid for
a period of three (3) years.
(1) This regulation shall apply to veterinary medicinal
products which require a veterinary prescription as per Article 34 of
Regulation (EU) 2019/6 and to products or substances that may not be
classified as veterinary medicinal products, but which may be deemed
by the Director to require a veterinary prescription for their
administration to animals
Provided that this regulation shall not apply to veterinary
prescriptions issued for the preparation, placing on the market and use
of medicated feed.
(2) No person shall alter a veterinary prescription unless
authorized to do so by the veterinary surgeon who has issued the
prescription
Provided that the veterinary surgeon who authorised that
the veterinary prescription be altered and the dispenser shall keep a
note to this effect.
(3) Veterinary prescriptions shall be printed or handwritten in
indelible ink, signed in original handwriting and rubber stamped by the
veterinary surgeon who issues the veterinary prescription
Provided that in the event that the veterinary prescription is
printed, the signature and rubber stamp of the veterinary surgeon shall
be made in ink which is different from the printing ink
Provided further that this regulation shall not be applicable
to electronic veterinary prescription.
(4) In addition to the elements listed in Article 105(5) of
Regulation (EU) 2019/6, a veterinary prescription issued in the
territory of Malta shall also include the following
(a) the name of veterinary medicinal products or
medicinal products for human use dispensed, including their
active substances and pharmaceutical form and strength;
(b) the quantity dispensed or the number of packs,
including pack size;
(c)
the disease treated or prevented;
(d) the name, signature and stamp of the dispenser of the
veterinary medicinal products or medicinal products for human
use, including the professional number, if available;
(e) the name and address of premises from where the
veterinary medicinal products or medicinal products for human
use are dispensed; and
(f) the dates when the veterinary medicinal products or
medicinal products for human use were dispensed.
(5) The dispenser shall not accept verbal instructions unless all
the following conditions are satisfied
(a) that the dispenser is satisfied that the verbal
instruction comes from a veterinary surgeon who by reason of an
emergency is unable to furnish a veterinary prescription;
(b) that the veterinary surgeon undertakes to furnish the
dispenser with a veterinary prescription within forty-eight (48)
hours of the verbal instruction; and
(c) that the product is dispensed in accordance with the
directions of the veterinary surgeon.
(6) If not all the products on the veterinary prescription are
dispensed, the dispenser shall make a note on the veterinary
prescription to that effect.
(7) In case more than one (1) product is listed on the veterinary
prescription and not all of them are dispensed from a single (1) place
from where veterinary medicinal products can be retailed in
accordance with the regulation 18, the dispenser shall make a note on
the veterinary prescription to that effect. The dispenser shall note on
the veterinary prescription which product and how many of the
products were dispensed. The dispenser shall keep an accurate account
of the course of action he has taken. The veterinary prescription may
then be given to another dispenser by the customer, whereupon if the
rest of the products are dispensed, it shall be considered as supplied in
its entirety
Provided that this regulation shall apply also to products
which are only partially dispensed from a single (1) place with the
remaining quantities of the same product dispensed from another
place.
(8) A veterinary prescription for veterinary medicinal products
that are not antimicrobials or that do not contain narcotic or
psychotropic drugs shall be valid for a period not exceeding six (6)
months from the date of issue.
(9) A veterinary prescription for veterinary medicinal products
containing narcotic or psychotropic drugs shall be valid for a period
not exceeding one (1) month from the date of issue.
(10) Pursuant to Article 105(12) of Regulation (EU) 2019/6, a
veterinary medicinal product or a medicinal product for human use
classified as subject to a veterinary prescription may be administered
personally by the veterinary surgeon without a veterinary prescription,
provided that they do not contain antimicrobials or narcotic or
psychotropic drugs.
(11) The veterinary surgeon, dispenser and the animal owner or
keeper shall keep the veterinary prescriptions for a period of not less
than five (5) years and shall be made readily available to the Director
upon his request.
(1) The Director shall provide the veterinary
prescriptions on which veterinary surgeons shall prescribe veterinary
medicinal products or medicinal products for human use.
(2) The printed version of a veterinary prescription shall remain
valid until such time as determined by the Director, who may decide
that it shall be substituted by an electronic version where all the
regulations apply mutatis mutandis.
(3) The electronic veterinary prescription shall be established
by the Director and used by the persons authorised to prescribe and
dispense.
(4) An electronic veterinary prescription shall be issued in such
a way as to unequivocally demonstrate the identity of the prescriber
and dispenser of veterinary medicinal products.
(5) The Director shall keep copies of the veterinary
prescriptions, in electronic format or hard copies, for a period of five
(5) years from the date of issue.
(1) Any person may administer veterinary medicinal Administration
of veterinary
products or medicinal products for human use which require a medicinal
veterinary prescription without the veterinary prescription in urgent products
medicinal
situations to alleviate suffering of the animal or impending spread of product
animals.
disease.
Provided that a visit to the place where the animal is kept by
the veterinary surgeon or a visit to the veterinary surgeon with the
animal, depending on the best practicable circumstance, shall take
place within forty-eight (48) hours of such an administration.
(2) Veterinary surgeons and persons authorised to dispense a
veterinary medicinal shall not supply for administration or administer
themselves, as may be applicable, veterinary medicinal product unless
such product is authorised by the Director.
(3) Products other than authorised veterinary medicinal
products whose therapeutic effectiveness is merely anecdotal shall be
used with caution. The administration of these products to food
producing species shall be subject to the approval of the Director. The
Director may ask the animal keeper to provide chemical data, clinical
documentation and studies about the possible environmental impact as
stipulated in the Gazette before granting his approval.
(4) Before prescribing a veterinary medicinal product or a
medicinal product that contain critically important antimicrobials, the
prescribing veterinary surgeon may take into account the results of
diagnostic laboratory information.
(5) Every registered or licensed establishment where food
producing animals are kept and are not excluded from the provisions of
Regulation (EU) 2017/625 of the European Parliament and of the
Council of 15 March 2017 on official controls and other official
activities performed to ensure the application of food and feed law,
rules on animal health and welfare, plant health and plant protection
products, amending Regulations (EC) No 999/2001, (EC) No 396/
2005, (EC) No 1069/2009, (EC) No 1107/2009, (EU) No 1151/2012,
(EU) No 652/2014, (EU) 2016/429 and (EU) 2016/2031 of the
European Parliament and of the Council, Council Regulations (EC) No
1/2005 and (EC) No 1099/2009 and Council Directives 98/58/EC,
1999/74/EC, 2007/43/EC, 2008/119/EC and 2008/120/EC, and
repealing Regulations (EC) No 854/2004 and (EC) No 882/2004 of the
European Parliament and of the Council, Council Directives 89/608/
EEC, 89/662/EEC, 90/425/EEC, 91/496/EEC, 96/23/EC, 96/93/EC
and 97/78/EC and Council Decision 92/438/EEC (Official Controls
Regulation) by the Director, and the establishments where animals are
kept for display to the public or for breeding purposes in the territory
of Malta shall have an appropriate animal health control programme
designed and implemented under the responsibility of a professional
registered with the Veterinary Surgeons Council
Provided that a register of the professionals responsible for
each animal health control programme shall be kept by the Director
Provided further that the Director may, from time to time,
publish requirements related to animal health control programmes in
the Gazette through a notice.
(6) Veterinary medicinal products and medicinal products for
human use that are used in the registered or licensed establishments
referred to in sub-regulation (5) shall only be kept in such
establishments.
(7) The records referred to in Article 108 of Regulation (EU)
2019/6 shall only be kept in the registered or licensed establishments
where food producing animals are kept in accordance with sub-
regulation (5).
(1) The marketing authorisation holder shall implement a
system for recording and reviewing complaints together with an
effective system for recalling promptly and at any time the veterinary
medicinal products in the distribution network.
(2) The marketing authorisation holder shall record and
investigate any complaint concerning a quality defect.
(3) The marketing authorisation holder or his representative
shall inform the Director of any quality defect that may result in a
recall or restriction on the supply. In so far as possible, the countries
where the products are marketed shall also be indicated.
The Director shall issue guidelines for the disposal of waste Safe disposal of
veterinary
derived from the manufacture, wholesale distribution, retail, research, medicinal
diagnosis and use of veterinary medicinal products. These guidelines products.
shall be issued in the Gazette through a notice.
(1) The persons referred to in Article 123(1) of Regulation Access by the
Director.
(EU) 2019/6, the holders of authorisation in accordance with
regulation 6, the holders authorisation in accordance with Article 5(6)
of Regulation (EU) 2019/6, the holders of registration in accordance
with Article 116 of Regulation (EU) 2019/6, the dispensers of
veterinary medicinal products and the brokers of veterinary medicinal
products shall allow the Director to carry out the controls referred to in
the same provisions by making the premises, documents, installations
and any equipment accessible at any reasonable time for inspection by
the Director.
(2) When the Director has valid reason to believe that any of
the persons referred to in sub-regulation (1) is acting in contravention
of any of the provisions of these regulations or Regulation (EU) 2019/
6, he shall notify the person concerned in writing through a notice
specifying the type of contravention and a time frame during which a
valid justification for his actions is to be provided.
(3) When the person concerned fails to provide a valid
justification within such time as specified in the notice, or if the reply
is unsatisfactory, the Director may suspend the activity of the
concerned person by means of a written notice specifying the reasons
for such suspension until such person is in compliance.
(4) The Director may also commence administrative or
disciplinary measures against the person for failure to fulfil his
obligations.
(5) Any authorisation or registration granted under these
regulations or Regulation (EU) 2019/6 shall not be renewed unless
remedial steps by the person to whom the notice is addressed are taken
as specified in the notice.
(1) Any person who contravenes or acts in breach of
Articles 5(1), 88(1)(a) and (b), 93, 99(1) and 134(1) of Regulation
(EU) 2019/6 and regulations 5, 6(2), 8, 11, 12(2), 15 and 16 shall be
guilty of an offence against article 38 of the Act and shall be liable on
conviction, to a fine (multa) exceeding five thousand euro (€5,000) but
not exceeding ten thousand euro (€10,000), or to imprisonment for a
term not exceeding six (6) months, or to both such fine and
imprisonment.
(2) Any person who contravenes or acts in breach of Articles
88(1)(c) and 127(1) of Regulation (EU) 2019/6 and regulations 6(9),
17(1), 22(1) and 29(1) shall be guilty of an offence against article 38 of
the Act and shall be liable on conviction, to a fine (multa) exceeding
thousand euro (€3,000) but not exceeding seven thousand euro
(€7,000), or to imprisonment for a term not exceeding three (3)
months, or to both such fine and imprisonment.
(3) Any person who contravenes or acts in violation of
regulation 35(1) shall be guilty of an offence against article 35 of the
Act and shall be liable on conviction, to a fine (multa) exceeding three
thousand euro (€3,000) but not exceeding seven thousand euro
(€7,000), or to imprisonment for a term not exceeding three (3)
months, or to both such fine and imprisonment.
(4) Any person who contravenes or acts in breach of Articles
58(6), (12) and (13), 95(1), 97(1), 101, 108(1), (2) and (5), and 121(1)
of Regulation (EU) 2019/6 and regulation 18(8) shall be guilty of an
offence against article 38 of the Act and shall be liable on conviction,
to a fine (multa) exceeding five hundred euro (€500) but not exceeding
one thousand euro (€1,000), or to imprisonment for a term not
exceeding two (2) months, or to both such fine and imprisonment.
(5) Any person who contravenes or acts in breach of any other
provision of Regulation (EU) 2019/6 and, or any of these regulations
shall be guilty of an offence against article 38 of the Act and shall be
liable on conviction, to a fine (multa) exceeding two hundred euro
(€200) but not exceeding four hundred euro (€400), or to imprisonment
for a term not exceeding one (1) month, or to both such fine and
imprisonment
Provided that the Director shall not be precluded from
proceeding in accordance with the provisions of article 61 of the Act.
Decisions in terms of these regulations shall be subject to a Right to appeal.
right of appeal before the Administrative Review Tribunal established
in terms of article 5(1) of the Administrative Justice Act by not later Cap. 490.
than twenty (20) days from the service of the decision, wherein the
person aggrieved by the said decision shall specify the reasons on the
basis of which the said decision of the Director should be cancelled or
modified
Provided that the decision shall become immediately
applicable and enforceable and shall remain applicable throughout the
term of appeal until final judgement by the Administrative Review
Tribunal, unless such decision is reversed by the said Tribunal and, or
the Court of Appeal or cancelled or modified by the Director
Provided further that any party, who feels aggrieved by a
decision of the Tribunal, may on a point of law, appeal to the Court of
Appeal in accordance with article 22 of the Administrative Justice Act. Cap. 490.
The Veterinary Medicinal Products Regulations are hereby Repeal and
saving.
repealed without prejudice to anything done or omitted to be done S.L. 437.47.
thereunder.
Immediately after the last item of the Second Schedule to Consequential
amendment.
the Administrative Justice Act there shall be added the words
"Veterinary Medicinal Products Regulations, S.L. 437.115, Superior/ Cap. 490.
Inferior Competence".
€3.69